Mer­ri­mack re­cruits Sanofi vet Richard Pe­ters for the top job; Ob­sE­va and Brae­burn de­tail their IPO shots

• Now that Mer­ri­mack Phar­ma­ceu­ti­cals $MACK has auc­tioned off its sole com­mer­cial drug to Ipsen and fo­cused square­ly on a set of top clin­i­cal can­di­dates, the Cam­bridge, MA-based biotech has re­cruit­ed long­time in­dus­try vet­er­an Richard Pe­ters to take the helm. The Har­vard-trained physi­cian is com­ing over from Sanofi Gen­zyme, where he was SVP of glob­al rare dis­eases, a $3 bil­lion per year busi­ness. “With the sup­port of the Board of Di­rec­tors and the ex­pect­ed near-term in­fu­sion of cap­i­tal, sev­er­al com­pelling clin­i­cal as­sets are now primed to re­al­ize their full po­ten­tial,” said Pe­ters in a state­ment. “To­geth­er with the rest of the man­age­ment team, we plan on con­tin­u­ing to take sub­stan­tial steps to grow our ro­bust pipeline to its full po­ten­tial, with an eye to­ward ear­ly da­ta read-outs, to max­i­mize val­ue cre­ation for pa­tients and stock­hold­ers.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.